COVID Drug Shows Promise Against Deadly Nipah Virus

Scientists may have found an unexpected weapon against one of the world's deadliest viruses, and it's already sitting on pharmacy shelves in some countries.

Researchers in China discovered that VV116, an antiviral pill approved for COVID-19 treatment in China and Uzbekistan, strongly blocks Nipah virus in laboratory tests and dramatically improved survival rates in infected animals. The study, published in Emerging Microbes & Infections, found that hamsters given the drug had a 66.7% survival rate, and their lungs, spleens, and brains showed much lower viral loads.

This matters because Nipah has no approved treatments or vaccines despite killing between 40% and 75% of people it infects. The World Health Organization lists Nipah as a priority disease requiring urgent research and development.

The virus spreads from bats to humans and can trigger severe brain swelling and respiratory illness. Just last month, the WHO confirmed two new Nipah cases in West Bengal, India, prompting health officials to trace and monitor contacts.

VV116 works by targeting an enzyme the virus needs to copy itself, essentially jamming the replication machinery before the infection can spread. Researchers tested it against both major Nipah strains: the Malaysian type and the even more dangerous Bangladeshi variant. The drug performed well against both.

Why This Inspires

The biggest reason for hope isn't just that VV116 works in early tests. It's that the drug already has regulatory approval for human use, which could shave years off the typical timeline for getting a new treatment to patients who need it.

Scientists from the Wuhan Institute of Virology, Shanghai Institute of Materia Medica, and Vigonvita Life Sciences collaborated on the research. They suggest VV116 might eventually work not just as a treatment but as prevention for healthcare workers, lab staff, and people living in outbreak zones.

The findings remain preclinical, meaning they show promise in labs and animals but haven't been tested in human Nipah patients yet. The next steps involve additional safety studies and carefully designed clinical trials to confirm whether the results translate to real world benefits.

Still, for communities that live under the shadow of Nipah outbreaks, and for the medical workers who respond to them, this research offers something that's been in short supply: a concrete reason to believe effective help might be on the way.